Taisho Pharmaceutical said on September 28 that it has filed an application in Japan seeking approval for an autoinjector version of its rheumatoid arthritis (RA) drug Nanozora (ozoralizumab). The announcement came two days after Nanozora obtained approval to become the…
To read the full story
Related Article
- Taisho’s Nanozora Autoinjector Goes on Sale in Japan
January 17, 2024
- Taisho’s Nanozora, 1st Nanobody Agent in Japan, Now Available
December 2, 2022
BUSINESS
- CSL Behring Japan Names Edward Wright as New Chief
October 2, 2026
- Takeda Welcomes 39 Prospective 2027 Hires in Japan
October 2, 2026
- Nippon Shinyaku Reports 5-Year Efficacy Data for DMD Hopeful
October 2, 2026
- Taiho’s ASTX030 Hits PIII Goal, US Filing Planned
October 2, 2026
- Ono Moves US Venture Capital Arm to Cambridge
October 2, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





